Outlook Therapeutics
NASDAQ: OTLKIselin, US · Delaware corporation · 1 known investors
Founders & leadership
Board
FG
Faisal G. SukhtianBoard director
YH
Yezan HaddadinBoard director
AH
Andong HuangBoard director
KJ
Kurt J. HilzingerBoard director
JA
Julia A. HallerBoard director
GA
Gerd AuffarthBoard director
RH
Randy H. ThurmanBoard director
JG
Julian GangolliBoard director
DG
Donald GriffithBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$181M disclosed across 11 of 13 rounds · 2015–2026
▶$5MofferedMay 2026 · 2 investors · BiotechnologyRule 506(b)
▶$5MofferedMay 2026 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Yezan HaddadinDirector
- Lawrence A. KenyonExecutive Officer, Director
- Faisal G. SukhtianDirector
- Randy H. ThurmanDirector
- Julian GangolliDirector
- Kurt J. HilzingerDirector
- Gerd AuffarthDirector
- Andong HuangDirector
- Offering amount
- $5M
- Finders' fees
- $485K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Apr 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$32MofferedJan 2025 · 10 investors · BiotechnologyRule 506(b)
▶$32MofferedJan 2025 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lawrence A. KenyonExecutive Officer, Director
- Jeff EvansonExecutive Officer
- Faisal G. SukhtianDirector
- Julia A. HallerDirector
- Gerd AuffarthDirector
- Yezan HaddadinDirector
- Randy H. ThurmanDirector
- Julian GangolliDirector
- Andong HuangDirector
- Kurt J. HilzingerDirector
- Offering amount
- $32M
- Finders' fees
- $1.4M
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedApr 2024 · 1 investors · BiotechnologyRule 506(b)
▶$5MraisedApr 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeff EvansonExecutive Officer
- Julia A. HallerDirector
- Julian GangolliDirector
- Gerd AuffarthDirector
- Andong HuangDirector
- C. Russell TrenaryExecutive Officer, Director
- Lawrence A. KenyonExecutive Officer, Director
- Kurt J. HilzingerDirector
- Yezan HaddadinDirector
- Randy H. ThurmanDirector
- Faisal G. SukhtianDirector
- Offering amount
- $13.3M
- Amount sold
- $5M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$60MraisedMar 2024 · 21 investors · BiotechnologyRule 506(b)
▶$60MraisedMar 2024 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeff EvansonExecutive Officer
- Andong HuangDirector
- Julia A. HallerDirector
- Kurt J. HilzingerDirector
- Lawrence A. KenyonExecutive Officer, Director
- Julian GangolliDirector
- Gerd AuffarthDirector
- Faisal G. SukhtianDirector
- Randy H. ThurmanDirector
- C. Russell TrenaryExecutive Officer, Director
- Yezan HaddadinDirector
- Offering amount
- $159M
- Amount sold
- $60M
- Finders' fees
- $3.6M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedJan 2023 · 1 investors · BiotechnologyRule 506(b)
▶$1MraisedJan 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Randy H. ThurmanDirector
- Andong HuangDirector
- Yezan HaddadinDirector
- Julia A. HallerDirector
- Gerd AuffarthDirector
- Julian GangolliDirector
- Lawrence A. KenyonExecutive Officer, Director
- Faisal G. SukhtianDirector
- C. Russell TrenaryExecutive Officer, Director
- Kurt J. HilzingerDirector
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$31.8MraisedJan 2023 · 1 investors · BiotechnologyRule 506(b)
▶$31.8MraisedJan 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Julia A. HallerDirector
- Andong HuangDirector
- C. Russell TrenaryExecutive Officer, Director
- Randy H. ThurmanDirector
- Julian GangolliDirector
- Lawrence A. KenyonExecutive Officer, Director
- Faisal G. SukhtianDirector
- Gerd AuffarthDirector
- Yezan HaddadinDirector
- Kurt J. HilzingerDirector
- Offering amount
- $31.8M
- Amount sold
- $31.8M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedFeb 2021 · 2 investors · BiotechnologyRule 506(b)
▶$4MraisedFeb 2021 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Julian GangolliDirector
- Randy ThurmanDirector
- Yezan HaddadinDirector
- Kurt J. HilzingerDirector
- Lawrence A. KenyonExecutive Officer, Director
- Faisal G. SukhtianDirector
- Andong HuangDirector
- Gerd AuffarthDirector
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16MraisedJun 2020 · 1 investors · BiotechnologyRule 506(b)
▶$16MraisedJun 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Julian GangolliDirector
- Kurt J. HilzingerDirector
- Randy ThurmanDirector
- Lawrence A. KenyonExecutive Officer, Director
- Jeff EvansonExecutive Officer
- Faisal G. SukhtianDirector
- Yezan HaddadinDirector
- Gerd AuffarthDirector
- Terry DagnonExecutive Officer
- Offering amount
- $16M
- Amount sold
- $16M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Seeking Alpha33 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Robinhood28 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Simply Wall St26 shared keywordsSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
TradingView26 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
StockTwits26 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
TipRanks26 shared keywordsFinancial analysis and stock research platform.
Companies competing with Outlook Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Outlook Therapeutics Aktie: CEO Jahr investiert 150.000 Dollarboerse-express.com · Aug 2026
Outlook Therapeutics (OTLK) Stock Looks Cheap On Hope But Pricey On Book Value - Simply Wall St Newssimplywall.st · Jul 2026
Outlook: 'Hold' - Caution On LYTENAVA FDA Approval And Cash Needs (NASDAQ:OTLK) | Seeking Alphaseekingalpha.com · Jul 2026Frequently asked questions
- Who founded Outlook Therapeutics?
- Outlook Therapeutics was founded by Pankaj Mohan.
- Who are Outlook Therapeutics's investors?
- Outlook Therapeutics's investors include Avoro Capital Advisors.
- How much funding has Outlook Therapeutics raised?
- Outlook Therapeutics has disclosed $181M raised across 11 of its 13 known rounds.
- Where is Outlook Therapeutics headquartered?
- Outlook Therapeutics is headquartered in Iselin, US.